INVEGA TRINZA® (paliperidone palmitate) Now Available Via Public Reimbursement

Effective immediately, INVEGA TRINZA® (paliperidone palmitate) is now reimbursed through the following public formularies:

  • Ontario Drug Benefit program as a General Benefit with Therapeutic Notes
  • Non-Insured Health Benefits (NIHB) program

For more information on gaining access to INVEGA TRINZA®, patients and their caregivers should speak with their treating physician.

CPA Appears Before Senate Committee Examining the Legalization of Cannabis

Yesterday, psychiatrist and mental health researcher Dr. Phil Tibbo appeared before the Senate Committee on Social Affairs, Science and Technology examining Bill C-45, the act that will set the course for cannabis legalization by the summer of 2018. Representing the CPA, Dr. Tibbo made several recommendations to the committee, most notably that Canadians should not be legally allowed to use marijuana until the age of 21, and that legislation should restrict the quantity and potency of the drug until they are 25. Dr. Tibbo was the principal author on CPA’s 2017 position statement, Implications of Cannabis Legalization on Youth and Young Adults. He also underscored the need for public education targeting youth and young adults around the effects early cannabis use can have on brain development. Dr. Robert Milin was also present speaking on behalf of the Canadian Academy of Child and Adolescent Psychiatry. Other witnesses included representatives from the Canadian Medical Association, the Canadian Nurses Association and the Canadian Research Initiative on Substance Misuse.

To see the full list of recommendations, click here.

SIRS Award Winners

We would like to take this opportunity to congratulate two of our members who were presented awards at the 6th Annual Schizophrenia International Research Society Conference held in Florence, Italy in April 2018.


Dr Ashok Malla received the award for Outstanding Clinical/Community Research.

Dr Lena Palaniyappan received the Rising Star award.

CCEIP at the IEPA 11 Symposium

It is a delight to announce that the CCEIP will present at the IEPA 11 Symposium on October 7-10 at the Westin Copley Place in Boston, Massachusetts, USA. Out of 80 symposium submissions, a stand out and fascinating topic which is highly relevant to the key themes of this years IEPA Conference, was selected to be presented, being the CCEIP’s submission discussing “Challenges and Opportunities in Quality of Care in Early Psychosis: Improving Outcomes at the System Level and Patient Level”

The date and time of individual symposium sessions will be posted to IEPA Conference website within the coming weeks, which can be found by clicking here

WPA 2017

CCEIP members had the opportunity to present a workshop at the WPA held in Berlin in early October.

Appropriate Antipsychotic Treatment Selection in Early Phase Psychosis

  • Dr. Phil Tibbo
  • Dr. Marc-André Roy

 

Click here to view the slide presentation:  WPA 2017 AP Selection Workshop

Scale for Early Psychosis Relapse Risk Assessment (SEPRRA)

Faculty:  Ashok Malla, MD, Rahul Manchanda, MD, Philip Tibbo, MD, Richard Williams, MD, Ridha Joober, MD

Sponsor: Schizophrenia Society of Canada Foundation and Otsuka-Lundbeck Alliance

In 2013, the CCEIP created an assessment tool for the prediction of relapse in early psychosis to be used in clinical settings. A multi-site study was conducted in 2016 to assess the feasibility and reliability of the tool, now named The Scale for Early Psychosis Relapse Risk Assessment (SEPRRA).

The SEPRRA tool has been assessed for feasibility and reliability, but before it can be used in routine clinical practice, the validity must be evaluated. If your clinic is interested in participating in the validation of this important tool, please reach out to Megan Connolly at megan@myelinassociates.ca for more details.

SEPPRA Relapse Prevention Tool

CPA 2017

CCEIP members had the opportunity to present two workshops at the CPA held in Ottawa earlier this month. Click here to access the following workshop presentations:

Appropriate Antipsychotic Treatment Selection in Early Phase Psychosis

  • Dr. Phil Tibbo
  • Dr. Marc-André Roy
  • Dr. Howard Margolese
  

Click here to view the slide presentation: M118 CPA 2017 AP selection workshop_for website_v2

The Effects of Cannabis Use in Early Phase Psychosis

  • Dr. Kathy Aitchison
  • Dr. Andrea Bardell
  • Dr. Phil Tibbo
  

Click here to view the slide presentation: M118 CPA 2017 – CCEIP Cannabis Workshop_for website

Click here to view the first video:

 

Click here to view the second video:

Atlantic Psychiatric Conference

CCEIP President Dr Phil Tibbo recently presented the CCEIP tools (including Relapse Risk Assessment, the Antipsychotic Treatment Selection tool, Initiation of Treatment for Early Phase Psychotic Disorders Order Set, OPTIMA, the Tool for Monitoring Antipsychotic Side Effects, and the iHope patient discussion tool) at the Atlantic Psychiatric Conference in Prince Edward Island. Evaluations were overwhelmingly positive.  Comments include:

  • Definitely will use the tools
  • Excellent
  • Excellent presenter and presentation to kick things off
  • Excellent use of examples
  • Great speaker – very practical and informative presentation. Probably one of the best speakers I have seen. Will be helpful in working with clients with psychosis/schizophrenia
  • Good resources for both tools and cannabis information
  • I am definitely checking out your website and will start using your tools
  • Importance of medication reactions
  • Importance of monitoring side effects
  • Integrating a new/specific addictions assessment tool
  • Looking forward to reviewing the tools more closely online as can see being a real use for them in clinical situation
  • Love the development of the tools – will definitely take a closer look at some for my own practice in an acute psychiatric setting
  • Provided tools which can be brought back to work and share with co-workers. Thanks
  • Super relevant. Awesome. Video how to assess motor side effects, availability of web resources
  • The importance of following up with any side effect
  • Use of tools in practice. Currently use AIMS tool, but good to know when proper re-testing be done again
  • Very clear and will visit the website for the forms
  • Very informative, learned the proper clinical tools in management of early phase of psychosis
  • Very interested in checking out the website and clinical tools
  • Will make it easier to identify the early stages of psychosis and relapse
  • Will promote viewing of the video online in licensed community care who care for individuals taking psychotropic medications

These tools are the focus of the RCPSC Accredited Program entitled “APPLY: Applying Clinical Tools – Early Psychosis program”, which was jointly developed by a national faculty, the Canadian Psychiatric Association, Janssen Inc., and Myelin & Associates. This program facilitates the opportunity for psychiatrists to apply clinical tools at point-of-care for the management of psychosis patients in the early phase of illness, and is available as either a Section 1 or Section 3 RCPSC accredited program. To find out more about a program in your area, contact program@myelinassociates.ca.

iHope Patient Discussion Tool

The iHope tool is available in both paper and electronic formats. It is meant to serve as a resource that can be used to support the conversation with newly diagnosed patients living with schizophrenia, reinforcing that patients can live well with this chronic illness.

FACULTY

Thomas Hastings, MD, FRCPC
Associate Clinical Professor, Department of Psychiatry, McMaster University, Hamilton, Ontario

Howard C. Margolese, MD, CM, MSc, FRCPC
Associate Professor, Department of Psychiatry, McGill University, Montréal, Québec

Phil Tibbo, MD, FRCPC
Dr Paul Janssen Chair in Psychotic Disorders
Professor, Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia

iHOPE PATIENT DISCUSSION TOOL VERSIONS

Print version here: iHope Tool

Online version here: iHope Tool (Note: The online version works best on Google Chrome)

*Please note that there is no audio for any of the videos

VIEWING INSTRUCTIONS

  1. Click the “Online” link to view the program online through your web browser (an internet connection is required; Google Chrome is the preferred browser).
  2. When the presentation is opened, you will be taken to a landing page. An introductory video will play automatically.
  3. Once the introductory video has finished, the presentation is divided into four different sections: Diagnosis, Symptoms, Journey, and Recovery, listed to the left of the video player. Access each of these sections by clicking on corresponding section titles.
  4. You can return to each section as many times as you would like.

Footnotes and References here: Footnotes and references

OPTIMA: Offering Patients Therapeutic Information on Medication Alternatives

Faculty – Howard Margolese
Sponsor – Janssen

A tool for patient engagement:

  • This tool allows for a systematic discussion about the option of LAIs with patients
  • It helps to make LAIs a choice, rather than a punishment

It is based on evidence that:

  • Relapses worsen the long term patient trajectory
  • The best way to avoid relapse is continuous antipsychotic treatment

Education Protocol for Health Care Providers – OPTIMA HCP Education Protocol

    • Who is appropriate?
    • When to discuss?
    • What to review?
    • How to initiate?

Patient Decision Aid